Der Anaesthesist

, Volume 66, Issue 11, pp 829–839 | Cite as

Differenzialindikation von Opioiden in der Schmerztherapie

  • J. Heyn
  • S. C. Azad


Aufgrund ihrer hohen analgetischen Potenz haben Opioide bis zum heutigen Tag einen großen Stellenwert in der Behandlung von akuten und insbesondere tumorbedingten chronischen Schmerzen. Da sich die einzelnen Opioide mitunter erheblich in ihren pharmakokinetischen und physikochemischen Eigenschaften unterscheiden, können sie nicht alle bei jedem Patienten gleichermaßen eingesetzt werden. Insbesondere bei Patienten mit Organfunktionsstörungen ist Vorsicht geboten. Darüber hinaus kann der Abbau der Opioide oder die Entstehung aktiver Metabolite durch genetische Faktoren oder Medikamenteninteraktionen maßgeblich beeinflusst werden. Die Kenntnis der Abbauwege sowie der pharmakologischen Besonderheiten einzelner Opioide kann daher helfen, Komplikationen zu vermeiden. Dieser Artikel widmet sich Pharmakologie, Anwendungsgebieten und Abbauwegen von Opioiden, die einen hohen Stellenwert in der Schmerztherapie haben.


Opioide Leberinsuffizienz Niereninsuffizienz Analgesie Pharmakokinetik 

Differential indications of opioids in pain therapy


Due to their strong analgesic potency opioids are highly effective in the therapy of acute and particularly cancer-induced chronic pain; however, the individual opioids differ considerably with respect to their pharmacokinetic and physicochemical properties and may therefore not be equally applicable for every patient. Caution should be taken especially in patients with impaired organ function. Furthermore, the metabolism of opioids leads to active or inactive metabolites. This process can be substantially influenced by genetic polymorphisms or drug interactions. Knowledge of all these factors for individual opioids, which influence the efficacy and side effects, is therefore crucial. In this review the pharmacology, clinical applications, metabolism and genetic factors of the most important opioids used for pain management are discussed.


Opioids Renal failure Hepatic failure Analgesia Pharmacology 


Einhaltung ethischer Richtlinien


J. Heyn und S.C. Azad geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.


  1. 1.
    Agundez JA, Ledesma MC, Ladero JM et al (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265–269CrossRefPubMedGoogle Scholar
  2. 2.
    Aklillu E, Persson I, Bertilsson L et al (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441–446PubMedGoogle Scholar
  3. 3.
    Al-Hasani R, Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115:1363–1381PubMedPubMedCentralGoogle Scholar
  4. 4.
    Arbaiza D, Vidal O (2007) Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig 27:75–83CrossRefPubMedGoogle Scholar
  5. 5.
    Bosilkovska M, Walder B, Besson M et al (2012) Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs 72:1645–1669CrossRefPubMedGoogle Scholar
  6. 6.
    Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229–243CrossRefPubMedGoogle Scholar
  7. 7.
    Brockmoller J, Kirchheiner J, Meisel C et al (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1:125–151CrossRefPubMedGoogle Scholar
  8. 8.
    Coller JK, Christrup LL, Somogyi AA (2009) Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 65:121–139CrossRefPubMedGoogle Scholar
  9. 9.
    Dahl ML, Johansson I, Bertilsson L et al (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520PubMedGoogle Scholar
  10. 10.
    Dai X, Brunson CD, Rockhold RW et al (2008) Gender differences in the antinociceptive effect of tramadol, alone or in combination with gabapentin, in mice. J Biomed Sci 15:645–651CrossRefPubMedGoogle Scholar
  11. 11.
    Daly AK, Brockmoller J, Broly F et al (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193–201CrossRefPubMedGoogle Scholar
  12. 12.
    Depriest AZ, Miller K (2014) Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther 3:1–15CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Dieterich M, Muller-Jordan K, Stubert J et al (2012) Pain management after cesarean: a randomized controlled trial of oxycodone versus intravenous piritramide. Arch Gynecol Obstet 286:859–865CrossRefPubMedGoogle Scholar
  14. 14.
    Dobe M, Hechler T, Behlert J et al (2011) Pain therapy with children and adolescents severely disabled due to chronic pain: long-term outcome after inpatient pain therapy. Schmerz 25:411–422CrossRefPubMedGoogle Scholar
  15. 15.
    Droney J, Levy J, Quigley C (2007) Prescribing opioids in renal failure. J Opioid Manag 3:309–316PubMedGoogle Scholar
  16. 16.
    Eichelbaum M, Burk O (2001) CYP3A genetics in drug metabolism. Nat Med 7:285–287CrossRefPubMedGoogle Scholar
  17. 17.
    Engeser P, Kuate Fokan E, Laux G et al (2016) Care of patients with cancer pain in general practices in Germany. Schmerz 30:266–272CrossRefPubMedGoogle Scholar
  18. 18.
    JANSSEN-CILAG (2014) Fachinformation zu PiritramidGoogle Scholar
  19. 19.
    Finnerup NB, Attal N, Haroutounian S et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–173CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction TAble. Indiana University School of Medicine, Indianapolis (/clinpharm/ddis/Clinical-table/)Google Scholar
  21. 21.
    Fukushima-Uesaka H, Saito Y, Watanabe H et al (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100CrossRefPubMedGoogle Scholar
  22. 22.
    Greenspan JD, Craft RM, Leresche L et al (2007) Studying sex and gender differences in pain and analgesia: a consensus report. Pain 132(Suppl 1):S26–S45CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Grond S, Radbruch L (1998) Weak opioids. Meta-analysis for the therapy of chronic pain. Schmerz 12:142–155CrossRefPubMedGoogle Scholar
  24. 24.
    Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43:879–923CrossRefPubMedGoogle Scholar
  25. 25.
    Grun B, Merkel U, Riedel KD et al (2012) Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol 74:854–863CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Guttler K (2012) Opioid effects – galenics make the difference. Anasthesiol Intensivmed Notfallmed Schmerzther 47:224–230CrossRefPubMedGoogle Scholar
  27. 27.
    Hauser W, Bock F, Engeser P et al (2015) Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz 29:109–130CrossRefPubMedGoogle Scholar
  28. 28.
    Hohne C, Donaubauer B, Kaisers U (2004) Opioids during anesthesia in liver and renal failure. Anaesthesist 53:291–303CrossRefPubMedGoogle Scholar
  29. 29.
    Jage J, Laufenberg-Feldmann R, Heid F (2008) Drugs for postoperative analgesia: routine and new aspects: Part 2: opioids, ketamine and gabapentinoids. Anaesthesist 57:491–498CrossRefPubMedGoogle Scholar
  30. 30.
    Karlsson M, Berggren AC (2009) Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 31:503–513CrossRefPubMedGoogle Scholar
  31. 31.
    King S, Forbes K, Hanks GW et al (2011) A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 25:525–552CrossRefPubMedGoogle Scholar
  32. 32.
    Kruger R, Meissner W, Zimmer A (2014) Misuse of opioid analgesics. An internet analysis. Schmerz 28:473–482CrossRefPubMedGoogle Scholar
  33. 33.
    Kullgren J, Le V, Wheeler W (2013) Incidence of hydromorphone-induced neuroexcitation in hospice patients. J Palliat Med 16:1205–1209CrossRefPubMedGoogle Scholar
  34. 34.
    Lauche R, Klose P, Radbruch L et al (2015) Opioids in chronic noncancer pain-are opioids different? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids of at least four week’s duration. Schmerz 29:73–84CrossRefPubMedGoogle Scholar
  35. 35.
    Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389–430CrossRefPubMedGoogle Scholar
  36. 36.
    Lindena G, Arnau H, Liefhold J (1998) Hydromorphone – review of pharmacological properties and therapeutic efficacy with special regard to a controlled release preparation. Schmerz 12:195–204CrossRefPubMedGoogle Scholar
  37. 37.
    Marschall U, L’hoest H, Radbruch L et al (2016) Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain 20:767–776CrossRefPubMedGoogle Scholar
  38. 38.
    Mercadante S (2015) Opioid metabolism and clinical aspects. Eur J Pharmacol 769:71–78CrossRefPubMedGoogle Scholar
  39. 39.
    Messerer B, Grogl G, Stromer W et al (2014) Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management. Schmerz 28:43–64CrossRefPubMedGoogle Scholar
  40. 40.
    Michel-Lauter B, Maier C, Schwarzer A (2012) Accidental levomethadone intoxication in a palliative patient. Schmerz 26:721–723CrossRefPubMedGoogle Scholar
  41. 41.
    Minoia P, Sciorsci RL (2001) Metabolic control through L calcium channel, PKC and opioid receptors modulation by an association of naloxone and calcium salts. Curr Drug Targets Immune Endocr Metabol Disord 1:131–137CrossRefPubMedGoogle Scholar
  42. 42.
    Moody DE, Fang WB, Morrison J et al (2011) Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend 118:479–483CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Murthy KS, Makhlouf GM (1996) Opioid mu, delta, and kappa receptor-induced activation of phospholipase C‑beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Mol Pharmacol 50:870–877PubMedGoogle Scholar
  44. 44.
    Nagi K, Pineyro G (2014) Kir3 channel signaling complexes: focus on opioid receptor signaling. Front Cell Neurosci 8:186CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Nelson DR, Koymans L, Kamataki T et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42CrossRefPubMedGoogle Scholar
  46. 46.
    Ninke T, Thoma-Jennerwein S, Blunk J et al (2015) Anesthesia and pain management during pregnancy. Anaesthesist 64:347–356CrossRefPubMedGoogle Scholar
  47. 47.
    Niscola P, Scaramucci L, Vischini G et al (2010) The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 11:752–758CrossRefPubMedGoogle Scholar
  48. 48.
    Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem 239:2370–2378PubMedGoogle Scholar
  49. 49.
    Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. Ii. solubilization, purification, and properties. J Biol Chem 239:2379–2385PubMedGoogle Scholar
  50. 50.
    Ostgathe C, Voltz R, Van Aaaken A et al (2012) Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone. Support Care Cancer 20:2105–2110CrossRefPubMedGoogle Scholar
  51. 51.
    Pergolizzi J, Boger RH, Budd K et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287–313CrossRefPubMedGoogle Scholar
  52. 52.
    Pleym H, Spigset O, Kharasch ED et al (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241–259CrossRefPubMedGoogle Scholar
  53. 53.
    Riley J, Eisenberg E, Muller-Schwefe G et al (2008) Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 24:175–192CrossRefPubMedGoogle Scholar
  54. 54.
    Sachse C, Brockmoller J, Bauer S et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295PubMedPubMedCentralGoogle Scholar
  55. 55.
    Schopper M, Fleckenstein J, Irnich D (2013) Gender differences in acute and chronic pain conditions. Implications for diagnosis and therapy. Schmerz 27:456–466CrossRefPubMedGoogle Scholar
  56. 56.
    Schuler M, Griessinger N (2015) Opioids for noncancer pain in the elderly. Schmerz 29:380–401CrossRefPubMedGoogle Scholar
  57. 57.
    Scordo MG, Caputi AP, D’arrigo C et al (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195–200CrossRefPubMedGoogle Scholar
  58. 58.
    Stamer UM, Stuber F (2007) Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 20:478–484CrossRefPubMedGoogle Scholar
  59. 59.
    Stein C (2016) Opioid receptors. Annu Rev Med 67:433–451CrossRefPubMedGoogle Scholar
  60. 60.
    Tafelski S, Beutlhauser T, Bellin F et al (2016) Incidence of constipation in patients with outpatient opioid therapy. Schmerz 30:158–165CrossRefPubMedGoogle Scholar
  61. 61.
    Turolo S, Tirelli AS, Ferraresso M et al (2010) Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 62:1159–1169CrossRefPubMedGoogle Scholar
  62. 62.
    Walker AH, Jaffe JM, Gunasegaram S et al (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 12:289PubMedGoogle Scholar
  63. 63.
    Walker VA, Hoskin PJ, Hanks GW et al (1988) Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 3:145–149CrossRefPubMedGoogle Scholar
  64. 64.
    Wehrmann T, Rausch D, Seiler KU et al (1997) Tilidine does not affect human sphincter of Oddi motility – a randomized, controlled study. Aliment Pharmacol Ther 11:987–992CrossRefPubMedGoogle Scholar
  65. 65.
    Weiss J, Sawa E, Riedel KD et al (2008) In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 378:275–282CrossRefGoogle Scholar
  66. 66.
    Wild JE, Grond S, Kuperwasser B et al (2010) Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 10:416–427CrossRefPubMedGoogle Scholar
  67. 67.
    Wu CY, Wittick JJ (1977) Separation of five major alkaloids in gum opium and quantitation of morphine, codeine, and thebaine by isocratic reverse phase high performance liquid chromatography. Anal Chem 49:359–363CrossRefPubMedGoogle Scholar
  68. 68.
    Zernikow B, Schiessl C, Wamsler C et al (2006) Practical pain control in pediatric oncology. Recommendations of the German Society of Pediatric Oncology and Hematology, the German Association for the Study of Pain, the German Society of Palliative Care, and the Vodafone Institute of Children’s Pain Therapy and Palliative Care. Schmerz 20:24–39CrossRefPubMedGoogle Scholar
  69. 69.
    Zollner C, Schafer M (2008) Opioids in anesthesia. Anaesthesist 57:729–740 (quiz 741–722)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  1. 1.Klinik für Anaesthesiologie, Interdisziplinäre Schmerzambulanz und TagesklinikLudwig-Maximilians Universität München (LMU)MünchenDeutschland

Personalised recommendations